<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39292423</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-024-01481-x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">A clinical trial of Epidiolex<sup>®</sup>, the only US FDA-approved cannabis-derived consumer product (CDP), discovered an interaction with an immunosuppressant (tacrolimus) that led to drug toxicity, highlighting the unique intersection of prescription and commonly unregulated consumer products.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to identify if similar drug-drug interactions (DDIs) are occurring among the consumer CDP market, even though they cannot be identified through trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched Reddit for subreddits related to CDPs or health, resulting in 63,561,233 posts. From these, we identified 190 posts discussing both immunosuppressants and CDPs. Two blinded investigators evaluated the following. (1) Was there a concern about a potential DDI between consumer CDPs and immunosuppressants? (2) Was there a unique adverse event attributed to a DDI between consumer CDPs and immunosuppressants?</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of these, 66 posts (35%) expressed concern about a potential DDI, such as "Hey, my partner wants to try my edibles … she's on Prograf [tacrolimus] and wants to talk to a stoner who's had a heart transplant." Four posts (2%) reported a unique DDI, such as "I have clinical results that are semi-anecdotal, showing the coordination to my halting substance use … It's the CBD. Shot my prograf to 30 at like 4 mg." Two of the four reported DDIs are similar to those first reported for Epidiolex. The remaining two reported DDIs include a potential cannabidiol (CBD)/sirolimus or delta-9-tetrahydrocannabinol (THC)/sirolimus interaction and a THC/tacrolimus interaction, both resulting in drug toxicity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case study is the first to report on DDIs involving consumer CDPs, including both CBD and THC products, as well as a broader class of immunosuppressants. This demonstrates the risks associated with using consumer CDPs alongside prescription medications while highlighting the need for development of increased surveillance to monitor consumer CDPs for drug safety signals, as well as comprehensive regulations that take into account the unique characteristics of the consumer marketplace.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0009-0003-6372-9405</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Altman Clinical and Translational Research Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wightman</LastName><ForeName>Gwenyth Portillo</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zechariah</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Altman Clinical and Translational Research Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qualcomm Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poliak</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Bryn Mawr College, Bryn Mawr, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Davey M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Altman Clinical and Translational Research Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dredze</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayers</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Altman Clinical and Translational Research Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA. ayers.john.w@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qualcomm Institute, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA. ayers.john.w@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, #333 CRSF 9500 Gilman Drive, La Jolla, CA, 92093, USA. ayers.john.w@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Johns Hopkins University Center of Excellence in Regulatory Science</GrantID><Agency>U.S. Food and Drug Administration</Agency><Country /></Grant><Grant><GrantID>Innovation</GrantID><Agency>U.S. Food and Drug Administration</Agency><Country /></Grant><Grant><GrantID>UL1TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39292423</ArticleId><ArticleId IdType="doi">10.1007/s40264-024-01481-x</ArticleId><ArticleId IdType="pii">10.1007/s40264-024-01481-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hansen C, Alas H, Davis E. Where Is Marijuana Legal? A Guide to Marijuana Legalization. Available at: https://www.usnews.com/news/best-states/articles/where-is-marijuana-legal-a-guide-to-marijuana-legalization . Accessed 9 Mar 2023.</Citation></Reference><Reference><Citation>Leas EC. The hemp loophole: a need to clarify the legality of delta-8-THC and other hemp-derived tetrahydrocannabinol compounds. Am J Public Health. 2021;111(11):1927–31. https://doi.org/10.2105/AJPH.2021.306499 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2021.306499</ArticleId><ArticleId IdType="pubmed">34618542</ArticleId><ArticleId IdType="pmc">8630489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JW, Caputi TL, Leas EC. The need for federal regulation of marijuana marketing. JAMA. 2019;321(22):2163. https://doi.org/10.1001/jama.2019.4432 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.4432</ArticleId><ArticleId IdType="pubmed">31095243</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration Office of the Commissioner. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD)</Citation></Reference><Reference><Citation>Leas EC, Hendrickson EM, Nobles AL, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3(10): e2020977. https://doi.org/10.1001/jamanetworkopen.2020.20977 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.20977</ArticleId><ArticleId IdType="pubmed">33057645</ArticleId><ArticleId IdType="pmc">7563067</ArticleId></ArticleIdList></Reference><Reference><Citation>Leas EC, Nobles AL, Caputi TL, Dredze M, Smith DM, Ayers JW. Trends in internet searches for cannabidiol (CBD) in the United States. JAMA Netw Open. 2019;2(10): e1913853. https://doi.org/10.1001/jamanetworkopen.2019.13853 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.13853</ArticleId><ArticleId IdType="pubmed">31642924</ArticleId><ArticleId IdType="pmc">6820034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Poe AR, Smith T, Elliott MR, Kruger DJ, Boehnke KF. Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and δ8-tetrahydrocannabinol among US adults. JAMA Netw Open. 2023;6(12): e2347373. https://doi.org/10.1001/jamanetworkopen.2023.47373 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.47373</ArticleId><ArticleId IdType="pubmed">38091045</ArticleId><ArticleId IdType="pmc">10719758</ArticleId></ArticleIdList></Reference><Reference><Citation>Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Published 4 Jan 2023. Available at: https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report . Accessed 9 Feb 2024.</Citation></Reference><Reference><Citation>Antoniou T, Bodkin J, Ho JMW. Drug interactions with cannabinoids. Can Med Assoc J. 2020;192(9):E206. https://doi.org/10.1503/cmaj.191097 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.191097</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsherbiny M, Li C. Medicinal cannabis—potential drug interactions. Medicines. 2018;6(1):3. https://doi.org/10.3390/medicines6010003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines6010003</ArticleId><ArticleId IdType="pubmed">30583596</ArticleId><ArticleId IdType="pmc">6473892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascorbi I. Drug interactions–principles, examples and clinical consequences. Dtsch Arzteblatt Int. 2012;109(33–34):546–55. https://doi.org/10.3238/arztebl.2012.0546 . (quiz 556).</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2012.0546</ArticleId></ArticleIdList></Reference><Reference><Citation>Létinier L, Bezin J, Jarne A, Pariente A. Drug–drug interactions and the risk of emergency hospitalizations: a nationwide population-based study. Drug Saf. 2023;46(5):449–56. https://doi.org/10.1007/s40264-023-01283-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-023-01283-7</ArticleId><ArticleId IdType="pubmed">37046156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. 2021;50(6):345–50. https://doi.org/10.31128/AJGP-02-21-5845 .</Citation><ArticleIdList><ArticleId IdType="doi">10.31128/AJGP-02-21-5845</ArticleId><ArticleId IdType="pubmed">34059837</ArticleId></ArticleIdList></Reference><Reference><Citation>Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med. 2020;382(8):697–705. https://doi.org/10.1056/NEJMoa1916433 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916433</ArticleId><ArticleId IdType="pubmed">31860793</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnasamy VP, Hallowell BD, Ko JY, et al. Update: characteristics of a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury—United States, August 2019–January 2020. MMWR Morb Mortal Wkly Rep. 2020;69(3):90–4. https://doi.org/10.15585/mmwr.mm6903e2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6903e2</ArticleId><ArticleId IdType="pubmed">31971931</ArticleId><ArticleId IdType="pmc">7367698</ArticleId></ArticleIdList></Reference><Reference><Citation>King BA, Jones CM, Baldwin GT, Briss PA. The EVALI and youth vaping epidemics—implications for public health. N Engl J Med. 2020;382(8):689–91. https://doi.org/10.1056/NEJMp1916171 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1916171</ArticleId><ArticleId IdType="pubmed">31951683</ArticleId><ArticleId IdType="pmc">7122126</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328–35. https://doi.org/10.2133/dmpk.22.328 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.22.328</ArticleId><ArticleId IdType="pubmed">17965516</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond C, Hannaford P. Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Saf. 2003;26(15):1065–74. https://doi.org/10.2165/00002018-200326150-00001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200326150-00001</ArticleId><ArticleId IdType="pubmed">14640771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonawane KB, Cheng N, Hansen RA. Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006–2014 database. J Manag Care Spec Pharm. 2018;24(7):682–90. https://doi.org/10.18553/jmcp.2018.24.7.682 .</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2018.24.7.682</ArticleId><ArticleId IdType="pubmed">29952714</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Commissioner. MedWatch: the FDA safety information and adverse event reporting program. FDA. Available at: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program . Accessed 10 Mar 2023.</Citation></Reference><Reference><Citation>Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 2014;37(5):343–50. https://doi.org/10.1007/s40264-014-0155-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0155-x</ArticleId><ArticleId IdType="pubmed">24777653</ArticleId><ArticleId IdType="pmc">4013443</ArticleId></ArticleIdList></Reference><Reference><Citation>Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944–8. https://doi.org/10.1111/ajt.15398 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15398</ArticleId><ArticleId IdType="pubmed">31012522</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidiolex Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf . Accessed 9 Mar 2023.</Citation></Reference><Reference><Citation>Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–9. https://doi.org/10.1056/NEJMp0911494 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp0911494</ArticleId><ArticleId IdType="pubmed">20220181</ArticleId><ArticleId IdType="pmc">3031980</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobles AL, Leas EC, Althouse BM, et al. Requests for diagnoses of sexually transmitted diseases on a social media platform. JAMA. 2019;322(17):1712. https://doi.org/10.1001/jama.2019.14390 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.14390</ArticleId><ArticleId IdType="pubmed">31688875</ArticleId><ArticleId IdType="pmc">6865226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobles AL, Johnson DC, Leas EC, et al. Characterizing self-reports of self-identified patient experiences with methadone maintenance treatment on an online community during COVID-19. Subst Use Misuse. 2021;56(14):2134–40. https://doi.org/10.1080/10826084.2021.1972317 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10826084.2021.1972317</ArticleId><ArticleId IdType="pubmed">34486471</ArticleId><ArticleId IdType="pmc">8820092</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul MJ, Dredze M. Social monitoring for public health. Springer International Publishing; 2017. https://doi.org/10.1007/978-3-031-02311-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-02311-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JW, Caputi TL, Nebeker C, Dredze M. Don’t quote me: reverse identification of research participants in social media studies. NPJ Digit Med. 2018;1(1):30. https://doi.org/10.1038/s41746-018-0036-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-018-0036-2</ArticleId><ArticleId IdType="pubmed">31304312</ArticleId><ArticleId IdType="pmc">6550214</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry AR. Patients’ perceptions and use of natural health products. Can Pharm J Rev Pharm Can. 2018;151(4):254–62. https://doi.org/10.1177/1715163518779409 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1715163518779409</ArticleId></ArticleIdList></Reference><Reference><Citation>PROGRAF (tacrolimus) Label. Published online 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050708s052,050709s044,210115s004lbl.pdf . Accessed 18 Feb 2024.</Citation></Reference><Reference><Citation>Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–92. https://doi.org/10.1039/C6NP00074F .</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6NP00074F</ArticleId><ArticleId IdType="pubmed">27722705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik B. Epidiolex rollout: $32,500 list price spurs critics as first cannabis drug hits shelves. Fierce Pharma. Available at: https://www.fiercepharma.com/marketing/epidiolex-launch-official-first-cbd-approved-by-fda-shelves-but-high-price-spurs-some . Accessed 9 Mar 2023.</Citation></Reference><Reference><Citation>Golder S, Norman G, Loke YK. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol. 2015;80(4):878–88. https://doi.org/10.1111/bcp.12746 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12746</ArticleId><ArticleId IdType="pubmed">26271492</ArticleId><ArticleId IdType="pmc">4594731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Yang H, Jiang L. Postmarketing drug safety surveillance using publicly available health-consumer-contributed content in social media. ACM Trans Manag Inf Syst. 2014;5(1):1–21. https://doi.org/10.1145/2576233 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2576233</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir S, Dredze M, Ayers JW. Mental health surveillance over social media with digital cohorts. In: Proceedings of the Sixth Workshop on Computational Linguistics and Clinical Psychology. Association for Computational Linguistics; 2019. pp 114–120. https://doi.org/10.18653/v1/W19-3013</Citation></Reference><Reference><Citation>Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. Expert Opin Drug Saf. 2018;17(11):1081–93. https://doi.org/10.1080/14740338.2018.1531847 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2018.1531847</ArticleId><ArticleId IdType="pubmed">30285501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazer D, Kennedy R, King G, Vespignani A. The parable of google flu: traps in big data analysis. Science. 2014;343(6176):1203–5. https://doi.org/10.1126/science.1248506 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1248506</ArticleId><ArticleId IdType="pubmed">24626916</ArticleId></ArticleIdList></Reference><Reference><Citation>Althouse BM, Scarpino SV, Meyers LA, et al. Enhancing disease surveillance with novel data streams: challenges and opportunities. EPJ Data Sci. 2015;4(1):17. https://doi.org/10.1140/epjds/s13688-015-0054-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1140/epjds/s13688-015-0054-0</ArticleId><ArticleId IdType="pubmed">27990325</ArticleId><ArticleId IdType="pmc">5156315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjoersvik O, Bate A. Black swan events and intelligent automation for routine safety surveillance. Drug Saf. 2022;45(5):419–27. https://doi.org/10.1007/s40264-022-01169-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01169-0</ArticleId><ArticleId IdType="pubmed">35579807</ArticleId><ArticleId IdType="pmc">9112242</ArticleId></ArticleIdList></Reference><Reference><Citation>Leas EC, Ayers JW, Desai N, Dredze M, Hogarth M, Smith DM. Using large language models to support content analysis: a case study of ChatGPT for adverse event detection. J Med Internet Res. 2024;26: e52499. https://doi.org/10.2196/52499 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/52499</ArticleId><ArticleId IdType="pubmed">38696245</ArticleId><ArticleId IdType="pmc">11099800</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49–58. https://doi.org/10.1038/s41591-022-02160-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02160-z</ArticleId><ArticleId IdType="pubmed">36646803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>